Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals Inc (SNDX) is a commercial-stage biopharmaceutical leader developing novel therapies for cancer and immune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative information on Syndax's oncology pipeline, including revumenib for acute leukemias and axatilimab for chronic GVHD. Our curated news collection features earnings reports, partnership announcements, trial results, and FDA communications – all essential for tracking the company's progress in targeted cancer therapeutics.
Key updates include developments in menin-KMT2A pathway research, CSF-1R antibody applications, and commercial readiness efforts. Bookmark this page for streamlined access to verified SNDX news, eliminating the need to monitor multiple sources.
Syndax Pharmaceuticals granted inducement awards to six new employees to purchase up to 100,600 shares of common stock under the 2023 Inducement Plan. The stock options will vest over four years, with gradual vesting conditions tied to the employees' continued service relationship.
Syndax Pharmaceuticals (Nasdaq: SNDX) will announce its first quarter 2024 financial results and provide a business update on May 8, 2024. The company will host a conference call and webcast to discuss the financial results and business progress.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
